Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma

Abstract

Meeting abstracts Axitinib, an inhibitor of vascular endothelial growth factor receptors (VEGFRs), is approved for second-line treatment of advanced renal cell carcinoma (aRCC). Pembrolizumab is a humanized monoclonal antibody that blocks binding of the immune-checkpoint receptor programmed death-1